Comparison of antibody levels for four different immunization schedules for PCVs

September 3, 2013

The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the infants after the booster dose at 12 months of age for almost all serotypes, according to a study in the September 4 issue of JAMA.

"The World Health Organization (WHO) estimated that more than 800,000 children younger than 5 years died from pneumococcal disease in 2000, making it the leading vaccine-preventable cause of death. Since the licensure in 2000 of the first 7-valent pneumococcal polysaccharide (PCV) for infants, many countries have added PCV to their existing national immunization programs. As a result, PCV differ between countries with respect to number of doses, age at , and intervals between doses," according to background information in the article. "The optimal for infants should provide maximal, sustained direct and indirect protection against while using a minimal number of doses. The latter is particularly relevant in the context of overcrowded national immunization programs, public resistance to vaccines, and cost-effectiveness estimates."

Judith Spijkerman, M.D., of the University Medical Centre, Utrecht, the Netherlands, and colleagues compared immunogenicity of 4 different schedules using the 13-valent PCV (PCV13) to assess the optimal primary regimen with respect to antibody induction. The of healthy term infants in a general community in the Netherlands was conducted between June 2010 and January 2011, with 99 percent follow-up until age 12 months. Infants (n = 400) were randomly assigned (1:1:1:1) to receive PCV13 either at ages 2,4, and 6 months (2-4-6); at ages 3 and 5 months (3-5); at ages 2,3, and 4 months (2-3-4); or at ages 2 and 4 months (2-4), with a booster dose at age 11.5 months.

The researchers found that one month after the booster dose, there were no differences in IgG (Immunoglobulin G) geometric mean concentrations (GMCs) between the schedules for 70 of 78 comparisons. "The 2-4-6 schedule was superior to the 2-3-4 schedule for 18C and 23F and superior to the 2-4 schedule for serotypes 6B, 18C, and 23F. For serotype 1, the 3-5 schedule was superior to the 2-4-6, 2-3-4, and 2-4 schedules."

Secondary outcomes (GMCs measured 1 month after the primary series, at 8 months of age, and before the booster) demonstrated differences 1 month after the primary series. "The 2-4-6 schedule was superior compared with the 3-5, 2-3-4, and 2-4 schedules for 3,9, and 11 serotypes, respectively. Differences between schedules persisted until the booster dose," the authors write.

"To our knowledge, this is the first randomized controlled trial investigating immunogenicity of PCV13 in 4 different primary immunization schedules currently used in most high income countries. The primary outcome of this study, GMCs l month after the booster dose, showed that there were no statistically significant differences between the 4 schedules in IgG levels for most serotypes. However, differences between schedules were noted in secondary analyses. … Our findings demonstrate that optimal timing of the primary series, i.e., older age at vaccinations combined with longer intervals between vaccinations, is important to maintain optimal during the period between the primary series and the booster dose."

"The choice of PCV schedule will require a balance between the need for early protection and maintaining protection between the primary series and the booster, in particular before herd effects offer clinical protection against vaccine serotype disease to as yet unvaccinated or incompletely vaccinated infants. When herd immunity is established, clinical relevance of the observed differences in immune responses may become of minor importance," the researchers conclude.

"A good deal remains to be learned about how best to use PCVs to protect the most vulnerable and the greatest number of community members," writes Katherine L. O'Brien, M.D., M.P.H., of the Johns Hopkins Bloomberg School of Public Health, Baltimore, in an accompanying editorial.

"Immunogenicity is just one aspect of biological effect, perhaps more important for some serotypes than others. Focus should remain squarely on ensuring that every child is immunized with at least 3 doses of PCV, beginning early in life and administered in a timely fashion. The study by Spijkerman and colleagues reassures that PCV products now in use provide a robust immune response across a range of dosing schedules and focuses attention on specific serotypes of concern. It is good news that PCVs are adaptable to various dosing schedules and therefore to demands of vaccine programs across countries. Emphasis on immunogenicity differences should not be separated from the larger context of protection at the individual level, pneumococcal disease epidemiology, vaccine program performance, and ultimately clear measures of disease outcome."

Explore further: First European randomized trial confirms new pneumococcal vaccine highly effective in infants

More information: doi:10.l001/jama.2013.228052
doi:10.l001/jama.2013. 228062

Related Stories

First European randomized trial confirms new pneumococcal vaccine highly effective in infants

November 15, 2012
A new conjugate vaccine is highly effective (93%) at preventing invasive pneumococcal disease (IPD; meningitis, sepsis, bacteremic pneumonia, and other blood-borne infections) in infants younger than 2 years who are the most ...

Administration of meningococcal vaccine with other routine infant vaccines appears effective

February 7, 2012
Administration of routine infant immunizations with a vaccine for serogroup B Neisseria meningitidis, a bacterium that is a cause of serious disease such as sepsis and meningitis, was effective against meningococcal strains ...

Recommended for you

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

Scientists propose novel therapy to lessen risk of obesity-linked disease

July 24, 2017
With obesity related illnesses a global pandemic, researchers propose in the Journal of Clinical Investigation using a blood thinner to target molecular drivers of chronic metabolic inflammation in people eating high-fat ...

Raccoon roundworm—a hidden human parasite?

July 24, 2017
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites—most notably, raccoon roundworms (Baylisascaris procyonis).

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.